Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 2/3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Melanoma 56Carcinoma, Non-Small-Cell Lung 56Carcinoma, Renal Cell 34Neoplasms 33Neoplasm Metastasis 29Colorectal Neoplasms 23Squamous Cell Carcinoma of Head and Neck 22Pancreatic Neoplasms 22Carcinoma, Hepatocellular 21Carcinoma, Transitional Cell 18Lung Neoplasms 17Glioblastoma 15Ovarian Neoplasms 14Triple Negative Breast Neoplasms 13Breast Neoplasms 13Urinary Bladder Neoplasms 11Stomach Neoplasms 11Head and Neck Neoplasms 10Uveal Melanoma 9Recurrence 8Myelodysplastic Syndromes 8Lymphoma 8Leukemia, Myeloid, Acute 8Advanced Cancer 8Small Cell Lung Carcinoma 7Multiple Myeloma 7Kidney Neoplasms 7Hodgkin Disease 7Hematologic Neoplasms 7Glioma 7

Interventions

pembrolizumab 7Magnetic Resonance Spectroscopy 5Cisplatin 5Specimen Handling 4Radiation 4Radiotherapy 3Biopsy 3motexafin gadolinium 2fludarabine 2Vorinostat 2Radiosurgery 2Fluorouracil 2Cyclophosphamide 2zimberelimab 1peposertib 1ipatasertib 1fludarabine phosphate 1dl1520 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Proton Therapy 1Platinum 1Paclitaxel 1Nivolumab 1Lidocaine 1L 778,123 1Immunohistochemistry 1Hyperthermia, Induced 1Gemcitabine 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Oropharyngeal Neoplasms × Nivolumab × Clear all
NCT03589339 2025-10-24

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Nanobiotix

Phase 1 Active not recruiting
145 enrolled
BreastGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mouth Neoplasms, Oropharyngeal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡